Ad
related to: cerebral adrenoleukodystrophy gene therapy- Case Studies
It’s about results, not just ideas
ZS helps clients drive growth
- Subscribe to ZS insights
Thought leadership articles
Newsletters from industries
- Solutions
Get Industry Expertise & Solutions
That Work in the Real World
- Industries
Deliver leading-edge analytics,
technology and strategy expertise
- Case Studies
Search results
Results from the WOW.Com Content Network
Elivaldogene autotemcel, sold under the brand name Skysona, is a gene therapy used to treat cerebral adrenoleukodystrophy (CALD). It was developed by Bluebird Bio and was given breakthrough therapy designation by the US Food and Drug Administration in May 2018.
For the childhood cerebral form, stem cell transplant and gene therapy are options if the disease is detected early in the clinical course. Adrenal insufficiency in ALD patients can be successfully treated.
Elivaldogene autotemcel (Skysona): treatment for cerebral adrenoleukodystrophy [9] Etranacogene dezaparvovec (Hemgenix): AAV-based treatment for hemophilia B [10] Exagamglogene autotemcel (Casgevy): treatment for sickle cell disease. [11] Gendicine: treatment for head and neck squamous cell carcinoma
Gene therapy is a medical technology that aims to produce a therapeutic effect through the manipulation of ... cerebral adrenoleukodystrophy July 2021 exagamglogene ...
For three types of leukodystrophies (X-linked adrenoleukodystrophy (X-ALD), metachromatic leukodystrophy (MLD) and Krabbe Disease (globoid cell leukodystrophy - GLD), gene therapy using autologous hematopoietic stem cells to transfer the healthy copy of the disease-causing gene with lentiviral vectors has been shown to succeed and has been used ...
Ayden's life pivoted quickly after a medical emergency on a trip in 2023 led to his April diagnosis of cerebral adrenoleukodystrophy, a rare brain condition for which there is no cure. The only ...
bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders. [1]The company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and has been approved for use by the European Medicines ...
The gene therapy will compete with Australia-based CSL Behring’s Hemgenix, a similar treatment that won FDA approval for hemophilia B in 2022. That drug has a similar list price of $3.5 million ...
Ad
related to: cerebral adrenoleukodystrophy gene therapy